First Trust Advisors LP Omeros Corp Transaction History

First Trust Advisors LP

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	SELL	$3.04 - $4.23 $46,630 - $64,883	-15,339 Reduced 8.61%	162,803 $660,000
Q1 2024 May 13, 2024	BUY	$2.88 - $4.89 $15,514 - $26,342	5,387 Added 3.12%	178,142 $614,000
Q4 2023 Feb 13, 2024	BUY	$1.08 - $3.63 $4,460 - $14,991	4,130 Added 2.45%	172,755 $564,000
Q3 2023 Nov 13, 2023	BUY	$2.81 - $5.69 $473,836 - $959,476	168,625 New	168,625 $492,000
Q3 2021 Nov 15, 2021	SELL	$13.4 - $16.3 $427,848 - $520,442	-31,929 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$14.81 - $19.13 $472,868 - $610,801	31,929 New	31,929 $474,000
Q1 2019 May 09, 2019	SELL	$11.65 - $17.72 $919,126 - $1.4 Million	-78,895 Closed	0 $0
Q4 2018 Feb 07, 2019	BUY	$10.72 - $16.73 $845,754 - $1.32 Million	78,895 New	78,895 $879,000
Q2 2018 Aug 02, 2018	SELL	$10.79 - $24.44 $674,018 - $1.53 Million	-62,467 Closed	0 $0
Q1 2018 Apr 23, 2018	SELL	$9.0 - $20.16 $390,753 - $875,286	-43,417 Reduced 41.0%	62,467 $698,000
Q4 2017 Feb 08, 2018	BUY	$13.26 - $22.86 $1.4 Million - $2.42 Million	105,884	105,884 $2.06 Million

120

25.6M

228K

630K

Ticker OMER
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 62,730,000
Market Cap $684M
Description
Omeros Corporation, a commercial-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, cancers related to dysfunction of the immune system, and addictive and compulsive disorders. The company's clinical program...

Get notified when there are updates to the investment portfolio of First Trust Advisors LP, based on Form 13F filings with the SEC.

Stay updated on First Trust Advisors LP with notifications on news.